Crooke, who is currently founder and CEO of n-Lorem, a nonprofit organization that works with families impacted by ultrarare conditions to find, develop, and provide new RNA treatments, will be a panelist on June 13 at the 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego, where he'll discuss his decades-long journey and the broader scientific and management practices that were critical for the success of Ionis Pharmaceuticals' drug discovery technology.

In founding Ionis, Crooke told ScienceBoard.net that he set out to create a unique culture "where innovation was the center" and "the only drive was to do basic science and to advance the technology."

Additional information on the BIO panel session, "'Hope Lies in Dreams' -- Ionis's Stan Crooke and the First Drug for SMA Patients," can be found on the convention's website.

Watch the video below to learn more.

Biotech industry to gather at BIO International Convention in San Diego
More than 11,000 attendees from around the globe will be in San Diego, June 13-16, for the 2022 Biotechnology Innovation Organization (BIO) International...

Ionis doses ALS patients with antisense medicine in clinical trial
Ionis Pharmaceuticals has dosed the first patients with ION541, an investigational antisense medicine developed to treat most forms of amyotrophic lateral...

Ionis' inhaled antisense drug shows promise as CF treatment
Ionis Pharmaceuticals has released positive data from a clinical trial evaluating IONIS-ENAC-2.5Rx, an investigational antisense medicine designed to...

Ionis, Genuity Science partner to advance RNA-targeted therapies
Ionis Pharmaceuticals and Genuity Science have entered a multiyear collaboration to accelerate the discovery and development of genetically validated...